当社グループは 3,000 以上の世界的なカンファレンスシリーズ 米国、ヨーロッパ、世界中で毎年イベントが開催されます。 1,000 のより科学的な学会からの支援を受けたアジア および 700 以上の オープン アクセスを発行ジャーナルには 50,000 人以上の著名人が掲載されており、科学者が編集委員として名高い
。オープンアクセスジャーナルはより多くの読者と引用を獲得
700 ジャーナル と 15,000,000 人の読者 各ジャーナルは 25,000 人以上の読者を獲得
Kshitija Iyer
A characteristic feature of the beginning of the XXI century medicine is that the achievement of bio-medical, diagnostic disciplines significantly outperforms progress to the clinic for the treatment of the most common diseases in the population. It atherosclerosis, diabetes, essential hypertension, and obesity, figuratively these diseases we call "metabolic pandemic". The frequency of these diseases in the populations of developed countries continues to increase, and all the efforts of clinicians and pharmaceutical companies do not produce the desired result, with the etiological factors are beginning to be better understood, which, however, cannot be said with regard to the pathogenesis. If the high expectations for the clinical use of genetics and genomics, gene polymorphisms have not justified, the possibility of metabolomics and proteomics are so great that their use in the diagnosis has not yet begun. We are not prepared to give the diagnostic interpretation of biochemical data in order to offer us the modern methods of physical chemistry, which at the same time, the concentration of dozens of proteins, substrates and metabolites. We cannot use the results of modern methods of diagnosis; we have no theoretical base - the modern theory of disease. It formed a large distance (gap) between the possibilities of the use of modern methods of research and its real application in the diagnosis of metabolic pandemics.